Literature DB >> 11378317

Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis.

J Rabinowitz1, M Davidson.   

Abstract

BACKGROUND: Patients who remain in hospital for an extended time pose a special therapeutic challenge.
OBJECTIVES: The goal of this study was to examine whether the acute response of long-term hospitalized schizophrenic patients differs between haloperidol and risperidone based on a post hoc, sub-analysis of data from a large double blind pivotal trial.
METHOD: Data on chronic schizophrenic patients who had been hospitalized for at least 60 days (median 351 days) prior to entering this 8-week randomized double blind controlled trial were examined. This included 75 patients treated with 4 mg of risperidone and 69 treated with 10mg of haloperidol. Changes in symptoms were assessed with the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) and the Clinical Global Impression (CGI). Data were analyzed using analysis of variance.
RESULTS: The analyses revealed that patients receiving risperidone improved significantly more than those treated with haloperidol.
CONCLUSIONS: Results suggest that the most often prescribed dose of risperidone, 4 mg, might be more effective for long-stay chronic schizophrenic patients than haloperidol 10mg.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11378317     DOI: 10.1016/s0920-9964(00)00163-8

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  6 in total

Review 1.  Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.

Authors:  Massimo Carlo Mauri; Silvia Paletta; Chiara Di Pace; Alessandra Reggiori; Giovanna Cirnigliaro; Isabel Valli; Alfredo Carlo Altamura
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

Review 2.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 3.  Risperidone versus placebo for schizophrenia.

Authors:  Ranganath D Rattehalli; Sai Zhao; Bao Guo Li; Mahesh B Jayaram; Jun Xia; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

Review 4.  Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.

Authors:  Massimo C Mauri; Lucia S Volonteri; Alessandro Colasanti; Alessio Fiorentini; Ilaria F De Gaspari; Silvio R Bareggi
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia.

Authors:  Amrita Prakash Singam; Abhishek Mamarde; Prakash B Behere
Journal:  Indian J Psychol Med       Date:  2011-07

Review 6.  Clinical pharmacology of atypical antipsychotics: an update.

Authors:  M C Mauri; S Paletta; M Maffini; A Colasanti; F Dragogna; C Di Pace; A C Altamura
Journal:  EXCLI J       Date:  2014-10-13       Impact factor: 4.068

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.